Biocept, Inc.

NasdaqCM:BIOC Voorraadrapport

Marktkapitalisatie: US$2.7m

Biocept Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Biocept has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 34.9% per year.

Belangrijke informatie

4.1%

Groei van de winst

91.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei34.9%
Rendement op eigen vermogen-10,554.1%
Nettomarge-2,255.5%
Laatste winstupdate30 Jun 2023

Recente prestatie-updates uit het verleden

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

Opbrengsten en kosten

Hoe Biocept geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:BIOC Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 231-31154
31 Mar 237-37175
31 Dec 2226-32236
30 Sep 2241-25256
30 Jun 2257-16276
31 Mar 2263-8266
31 Dec 2161-3215
30 Sep 21662215
30 Jun 2155-2204
31 Mar 2144-7185
31 Dec 2027-18165
30 Sep 2011-25145
30 Jun 206-26135
31 Mar 206-28135
31 Dec 196-25135
30 Sep 195-26135
30 Jun 194-27135
31 Mar 193-25125
31 Dec 183-25134
30 Sep 183-25134
30 Jun 184-24144
31 Mar 184-24144
31 Dec 175-22143
30 Sep 175-20133
30 Jun 175-19133
31 Mar 175-18123
31 Dec 163-18123
30 Sep 162-19113
30 Jun 161-19113
31 Mar 161-18103
31 Dec 151-17103
30 Sep 150-1693
30 Jun 150-1684
31 Mar 150-1574
31 Dec 140-1674
30 Sep 140-1464
30 Jun 140-1354
31 Mar 140-1243
31 Dec 130-933
30 Sep 130-1024
30 Jun 130-1024
31 Mar 130-1135
31 Dec 120-1237

Kwaliteitswinsten: BIOC is currently unprofitable.

Groeiende winstmarge: BIOC is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: BIOC is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.

Versnelling van de groei: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Rendement op eigen vermogen

Hoge ROE: BIOC has a negative Return on Equity (-10554.14%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden